Travere Therapeutics (TVTX) stock surged over 40% pre-market, aiming for near 20-year highs after the FDA approved Filspari as the first treatment for FSGS. Analysts at Canaccord and Citi raised price targets, projecting strong peak sales of $547 million by 2032 despite a narrower label.